Personnel

Positive Research Findings Accelerate HepaLife's Development of Artificial Liver Device

Published in Cancer Weekly, March 6th, 2007

HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) announced the appointment of Stem Cell Systems GmbH (Germany) among plans to accelerate development of a bioreactor system for the Company's first-of-its-kind artificial liver device, following favorable new research outcomes.

HepaLife announced that in ongoing research, scientists have demonstrated that the Company's patented PICM-19 cells have unique characteristics distinct from other cells, and are able to successfully mimic the human liver's response in several important ways. Among other research outcomes, important liver specific activity levels in the PICM-19 cells were up to three times higher than...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry